* Jaguar Health Inc JAGX.OQ JAGX.O is expected to show a
rise
in quarterly revenue when it reports results on August 11
(estimated).
* The San Francisco California-based company is expected to
report a 705.2% increase in revenue to $3.1 million from $385
thousand a year ago, according to the estimate from one analyst,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Jaguar Health Inc
is for
a loss of 22 cents per share. For the same quarter last year,
the company reported a loss of 30 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Jaguar
Health Inc
is $10.88, above its last closing price of $0.28.
This summary was machine generated August 10 at 02:01 GMT. All
figures in US dollars unless otherwise stated